FDA Approves Groundbreaking iDose ® TR for Glaucoma Treatment Following Successful Clinical Trials Conducted by Parkhurst NuVision and Glaukos
Parkhurst NuVision, a leading ophthalmic clinic and Glaukos have reached a significant milestone with the U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for iDose® TR (travoprost intracameral implant) 75 mcg. This pioneering prostaglandin analog... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 19, 2023 Category: Pharmaceuticals Tags: TRI FDA Source Type: news

iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst
Thursday, the FDA approved Glaukos Corporation's GKOS marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension or open-angle…#fda #glaukoscorporation #idosetr #williamblair #idose (Source: Reuters: Health)
Source: Reuters: Health - December 15, 2023 Category: Consumer Health News Source Type: news

FDA Approves Implant for Glaucoma FDA Approves Implant for Glaucoma
An intracameral implant that releases travoprost into the eye over an extended period to lower intraocular pressure in glaucoma and ocular hypertension will be available commercially in early 2024.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 15, 2023 Category: Drugs & Pharmacology Tags: Ophthalmology Source Type: news

FDA Approves iDose TR (travoprost intracameral implant) for the Treatment of Glaucoma
ALISO VIEJO, Calif.--(BUSINESS WIRE) December 14, 2023 -- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2023 Category: Drugs & Pharmacology Source Type: news

Implant for Ocular Hypertension, Glaucoma Gets FDA Green Light
(MedPage Today) -- The FDA approved the travoprost intracameral implant (iDose TR) for treatment of ocular hypertension and glaucoma, device developer Glaukos announced on Thursday. The implant is designed to provide long-duration treatment for... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 14, 2023 Category: American Health Source Type: news

Travatan Z (Travoprost Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 4, 2019 Category: Drugs & Pharmacology Source Type: news

Glaukos ’ iStent Has Strong Showing in 5-Year Data
This study shows that not only are Glaukos’ iStents as effective as once-daily topical travoprost in controlling IOP, but they also succeed at maintaining IOP reductions over the long-term with fewer additional medications.” The San Clemente, CA-based company has been on full court press for a while now. Earlier this year, at the 37th annual J.P. Morgan Healthcare Conference, the company unveiled a series of products and initiatives that would see it transition into a hybrid surgical, pharmaceutical, and medical device company.     (Source: MDDI)
Source: MDDI - April 16, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Glaukos touts 5-year study of glaucoma stents
This study shows that not only are Glaukos’ iStents as effective as once-daily topical travoprost in controlling IOP, but they also succeed at maintaining IOP reductions over the long-term with fewer additional medications.” Three-year outcomes of this study were published in 2016 in Ophthalmology and Therapy. The most recent article detailing five-year outcomes may be accessed online here. “This latest publication represents the first-ever five-year, protocol-driven, randomized evaluation of standalone iStent implantation in newly diagnosed glaucoma patients,” said Glaukos prez & CEO Thomas Burns. “Moreover,...
Source: Mass Device - April 15, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Clinical Trials Featured Implants News Well Optical/Ophthalmic Vision Glaukos Ivantis Source Type: news

Glaukos Keeps Its Eye on the Prize at J.P. Morgan
Glaukos is probably at the top of its game when it comes down to maintaining a presence in the micro-invasive glaucoma surgery (MIGS) market. The San Clemente, CA-based company reaffirmed its laser-like focus on the market during a presentation at the 37th annual J.P. Morgan Healthcare Conference earlier on Wednesday. Glaukos’ CEO Thomas Burns began his presentation speaking on the strengths of the firm and its goals going forward. “Our mission is aspirational,” Burns said. “As a company we are seeking to transform glaucoma therapy, and in doing so we ...
Source: MDDI - January 10, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Glaukos touts IOP, medication use reductions in iStent trial
Glaukos (NYSE:GKOS) today released results from a study of its iStent trabecular micro-bypass stent exploring its use during cataract surgery in patients with severe open-angle glaucoma, touting significant reductions in intraocular pressure and medication use. The San Clemente, Calif.-based company’s iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP. Results were published in the January issue of the Journal of Glaucoma. “Although the iStent is currently ...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news

Glaukos touts Ph2 glaucoma trial for drug-eluting implant
Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost within the eye and when it’s depleted, the iDose is removed and replaced. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos touts Ph2 glaucoma trial for drug-eluting implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Glaukos Source Type: news

Glaukos wins FDA nod for IDE trial of iStent SA
Glaukos (NYSE:GKOS) said today it won FDA investigational device exemption to launch a pivotal study of its iStent SA trabecular micro-bypass system designed to treat glaucoma. The San Clemente, Calif.-based company’s iStent SA is designed to reduce intraocular pressure in psuedophakic, mild-to-moderate open-angle, pigmentary or psuedoexfoliative glaucoma patients, the company said. The system includes 2 micro-scale titanium stents in an auto-injection system which can be injected into trabecular meshwork locations through a single corneal entry point to restore physiological outflow of aqueous humor into the Sclemm...
Source: Mass Device - December 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Glaukos Source Type: news

Glaukos touts iStent study with topical travoprost
Glaukos (NYSE:GKOS) touted data today from a 53-patient glaucoma study showing that its iStent device combined with topical travoprost reduced mean intraocular pressure by 35% after 18 months of follow-up. The company’s flagship device is designed to lessen IOP by restoring the natural outflow of aqueous humor through the conventional pathway in a patient’s eye. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos touts iStent study with topical travoprost appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Stents Wall Street Beat Glaukos Source Type: news

Envisia reports positive interim results from Phase II trial of ENV515 in glaucoma
US-based clinical-stage biotechnology firm Envisia Therapeutics has reported positive interim results from the second cohort of the ENV515 (travoprost XR) Phase II trial to treat patients with glaucoma. (Source: Drug Development Technology)
Source: Drug Development Technology - February 6, 2017 Category: Pharmaceuticals Source Type: news

Glaukos touts IOP reduction in pseudophakic iStent study
Glaukos (NYSE:GKOS) today released data from a study of its iStent trabecular micro-bypass stent, touting reduced intraocular pressure when implanted in pseudophakic eyes with open-angle glaucoma. Data from the study was recently published in the Journal of Glaucoma, the Laguna Hills, Calif.-based company said. Glaukos’ iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP, the company said. Pseudophakic eyes are eyes in which the natural lens has been removed and replace...
Source: Mass Device - December 12, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news